Skip to content

Study · Not a test of the peptide alone · 1991

3 results

Antitumor activity of a novel chimera tumor necrosis factor (TNF-STH) constructed by connecting rTNF-S with thymosin beta 4 against murine syngeneic tumors.

Noguchi K, Inagawa H, Tsuji Y, Morikawa A, Mizuno D, Soma G

Journal of immunotherapy : official journal of the Society for Biological Therapy1 Apr 1991Cited by 8 (Europe PMC)

PMID2043590 (opens in a new tab)DOI10.1097/00002371-199104000-00004 (opens in a new tab)PepBankPUB-02043590
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In mice, the chimera rTNF-STH (TNF fused with thymosin beta‑4) induced tumor necrosis at a smaller intravenous dose than rTNF-alpha or rTNF-S.

    In plain wordsIn mice, a TNF protein joined to thymosin beta‑4 caused tumor necrosis at a smaller dose than regular TNF.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTumor necrosis induction
    Study

    mousen: not reported in source

    Comparator
    rTNF-alpha or rTNF-S
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Tumor necrosis was induced by intravenous injection of a smaller amount of rTNF-STH (1 x 10(3) U/mouse, 0.67 microgram/mouse) than rTNF-alpha or rTNF-S (1 x 10(4) U/mouse, 2.5-5 micrograms/mouse).

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In mice with Meth A fibrosarcoma, B16 melanoma, MH134 hepatoma or Lewis lung carcinoma, the chimera rTNF-STH had significant antitumor effects at its maximum tolerable dose, which conventional rTNF-alpha did not cause at the same dose.

    In plain wordsIn mice with four tumor types, a TNF protein joined to thymosin beta‑4 had antitumor effects that regular TNF lacked at that dose.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseAntitumor effect against syngeneic tumors
    Study

    mousen: not reported in source

    Comparator
    Conventional rTNF-alpha
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Significant antitumor effects of rTNF-STH to Meth A fibrosarcoma, B16 melanoma, MH134 hepatoma, or Lewis lung carcinoma (3LL) were observed by systemic injection of rTNF-STH at the maximum tolerable dose of 1 x 10(4) U/mouse (6.7 micrograms/mouse); this dose did not cause regression of tumors by conventional rTNF-alpha

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Pharmacokinetics

    The average serum half-life of the chimera rTNF-STH was about 110 min, 15 times longer than that of the original TNF-SAM1 (7.5 min).

    In plain wordsIn mice, a TNF protein joined to thymosin beta‑4 stayed in the blood about 15 times longer than the original TNF.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseSerum half-life
    Study

    mousen: not reported in source

    Comparator
    TNF-SAM1
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    half-life
    ≈ 110 min
    rTNF-STH
    half-life
    7.5 min
    TNF-SAM1

    Source sentences

    Summary
    The average calculated half-life of the chimera protein is about 110 min, which is 15 times longer than that of original TNF-SAM1 (7.5 min).

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.